Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar preston18 (< 20) Submitted: 10/7/2009 5:25:30 PM : Outperform Start Price: $23.13 ACOR Score: -26.41

Outperform

Featured Broker Partners


Advertisement